** Shares of Lumos Diagnostics LDX.AX more than double in value to A$0.080
** Stock posts its biggest intraday pct gain since July 2023
** Healthcare tech co signs U.S. distribution and supply agreement for FebriDx valued at up to $317 million
** FebriDx is a rapid point of care test that helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections through a fingerstick blood sample
** Agreement signed with Hong Kong-headquartered PHASE Scientific International
** About 15.8 million shares change hands, compared with the 30-day average volume of 663,247
** YTD, shares up 108.6%
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com;))